Topic: Jason Kantor

Alexa shares jump after plan backed for Adasuve

0 . Alexza Pharmaceuticals climbed Tuesday after a U.S. panel backed the drugmaker's plan to sell an inhaled antipsychotic drug that may put some...
Seattle Genetics (SGEN) lost more than a quarter of its value this month on worries that the company's newly approved cancer drug Adcetris won't...
After a weekend of wowing scientific and investor communities, Pharmasset (VRUS) is rising Monday as the company moves forward with a...

Betting on Spectrum's Cancer Drug

In the next couple of weeks, Spectrum Pharmaceuticals (SPPI) expects to get word from the Food and Drug Administration on whether the company's...

Cubist Soars on Settlement

Big drug makers are accustomed to fighting patent challenges but smaller players have their own battles, which can have a bigger impact on...
Roche and partner Curis(CRIS) said Monday that an experimental drug met a pre-defined response rate target in a mid-stage study that enrolled...
PDL BioPharma Inc. (PDLI) Q3 2010 Earnings Call Transcript November 10, 2010 4:30 pm ET. I'll now turn the call over to John McLaughlin, President and CEO of PDL BioPharma.. As background, our SPCs were applied for and granted by ...
Before we begin, I'd like to advise you this conference call contains forward-looking statements regarding our future expectations, plans and prospects within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to the following; the expected ...
Synta Pharmaceuticals Corp. (SNTA) Q1 2010 Earnings Conference Call May 04, 2010 10:00 am ET. With me are Dr. Safi Bahcall our Chief Executive Officer, Keith Ehrlich, our Chief Financial Officer and Dr. Vojo Vukovic, Synta's Chief Medical Officer. This ...
With me today are Clay Siegall, President and Chief Executive Officer, Todd Simpson, Chief Financial Officer, Eric Dobmeier, Chief Business Officer and Tom Reynolds, Chief Medical Officer.. We are on track to report data from our pivotal Hodgkin lymphoma trial in the ...